Market News AIOpen the app

LXEO stock news · Lexeo Therapeutics

Stories about Lexeo Therapeutics (LXEO) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for LXEO

Follow Lexeo Therapeutics (LXEO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LXEO
Free on the App Store and Google Play, or on the web.
  1. Nov 17, 2026, 9:04 AM ET · Trial

    Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 and Q3 2026 Financial Results

    Good for LXEO

    Lexeo reported LX2020 interim results with mean reductions of 80% in NSVT and 44% in premature ventricular contractions. This favors LXEO, with cash expected to last into 2028.

  2. Nov 16, 2026, 1:34 PM ET · Market

    Lexeo Therapeutics showed an 80% drop in heart rhythm issues in its study on genetic heart disease.

    Good for LXEO

    Lexeo reported an 80% average drop in one heart rhythm problem among 7 high-dose patients, and a 44% drop in early extra beats. The results favor Lexeo.

  3. Nov 16, 2026, 7:04 AM ET · Results

    Lexeo Therapeutics, Inc.: Results of Operations and Financial Condition (LXEO)

    Good for LXEO

    Lexeo reported an 80% mean drop in one heart-rhythm measure and a 44% mean drop in another in high-dose groups. The early results make this update positive for Lexeo.

  4. Nov 15, 2026, 9:09 AM ET · Market

    Lexeo Therapeutics will share its third quarter 2026 results and an update on LX2020 on November 16, 2026.

    Neutral

    Lexeo set November 16, 2026, to report third-quarter results and discuss its LX2020 trial. No results or trial findings are included, so the notice does not change its outlook.

  5. Sep 29, 2026, 4:22 PM ET · Market

    Lexeo Therapeutics finished buying Mantle and paid with cash and company shares.

    Neutral

    Lexeo completed its purchase of Mantle using cash and shares, with more payments possible if milestones are met. The filing does not show how the deal changes Lexeo's prospects.

  6. Sep 29, 2026, 4:21 PM ET · Market

    Lexeo Therapeutics finished buying Mantle for $8.3 million in cash and stock.

    Neutral

    Lexeo completed its purchase of Mantle for cash and shares, with more payments tied to milestones. The filing gives no results showing what Mantle adds, so the outlook is unchanged.

  7. Sep 22, 2026, 7:23 AM ET · Deal

    Lexeo Therapeutics, Inc. has signed an important agreement to merge with Mantle Therapeutics Inc.

    Neutral

    Lexeo announced a merger to acquire Mantle for $5.3M cash plus $3.0M stock; deal size and uncertain obligations leave Lexeo's standing unchanged.